Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.

@article{BloechlDaum2006DelayedNA,
  title={Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.},
  author={Brigitte Bloechl-Daum and Robert R. Deuson and Panagiotis Mavros and M Hansen and J{\o}rn Herrstedt},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 27},
  pages={
          4472-8
        }
}
PURPOSE Chemotherapy-induced nausea and vomiting (CINV) are major adverse effects of cancer chemotherapy. We compared the impact of acute (during the first 24 hours postchemotherapy) and delayed (days 2 through 5 postchemotherapy) CINV on patients' quality of life (QoL) after highly or moderately emetogenic chemotherapy (HEC and MEC, respectively). PATIENTS AND METHODS This prospective, multicenter, multinational study was conducted in 14 medical practices on cancer patients undergoing either… Expand
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
TLDR
Despite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection and nausea was worse controlled than vomiting. Expand
Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life
TLDR
The results of the study confirm the detrimental effect of CINV on patients’ quality of life (QoL) despite the use of antiemetic prophylaxis (5HT3 receptor antagonist, steroids, and dopamine receptor antagonists). Expand
Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
TLDR
Addition of aprepitant reduced CINV impact on daily life compared with standard antiemetic therapy. Expand
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study
TLDR
CINV continues to be a problem that adversely affects the daily lives of patients and more attention should be paid to adjustment of antiemetic treatment to cover CINV complaints, later during the chemotherapy cycle. Expand
Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study
TLDR
The current use of antiemetic prophylaxis according to the recommended guideline appears to effectively control delayed CINV in patients undergoing LEC, and patients with the abovementioned risk factors should be carefully observed, and their treatment should be adjusted according to their symptoms. Expand
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
TLDR
GCCP reduces the incidence of CINV after single-day HEC and MEC, and this prospective, observational multicenter study enrolled chemotherapy-naive adults initiating single- day highly or moderately emetogenic chemotherapy for cancer. Expand
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
TLDR
Compared with control, rolapitant improved quality of life in patients receiving HEC or MEC, and significantly improved the FLIE total score. Expand
Addition of aprepitant prevents chemotherapy-induced vomiting and nausea moderately when 5-Hydroxytryptamine-3 receptor antagonists and dexamethasone failed
Aprepitant is one of the effective antiemetic drugs that usually used for prevention of Capecitabine and oxaliplatin (XELOX) chemotherapy-induced nausea and vomiting (CINV). We aimed to evaluate theExpand
Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
TLDR
The addition of 5mg/day of oral olanzapine to standard therapy can reduce the frequency of CINV and improve QOL of patients receiving highly or moderately emetogenic chemotherapy. Expand
Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)
TLDR
These data confirm previous reports that subgroups of patients may be more prone to acute and delayed CINV, and suggest future CinV study design may benefit from a more individualized approach to CINv management. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy
TLDR
It can be concluded that patients who experience PCNV experience a significant negative impact on their HRQOL and that this impact can be attributed in large part to their experience of nausea and vomiting. Expand
Effect of postchemotherapy nausea and vomiting on health-related quality of life
TLDR
PCNV adversely affects several quality-of-life domains, but patients with only nausea experience less disruption than do those with both nausea and vomiting, and by 2–4 weeks after chemotherapy all HQL scores had either returned to their baseline levels or were better than baseline. Expand
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index—Emesis (FLIE) with 5-day recall
TLDR
The 5-day FLIE had adequate measurement characteristics for studying the impact of CINV on patients' daily lives during the period covering both the acute and delayed phases. Expand
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
TLDR
The aprepitant regimen was more effective than the control regimen for prevention of CINV in patients receiving both an anthracycline and cyclophosphamide, and both treatments were generally well tolerated. Expand
Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.
TLDR
Patients about to receive moderately or highly emetogenic chemotherapy should be screened for these factors and additional measures, such as behavior modification and modification of antiemetic therapy, should be considered in attempts to improve the control of PCNV. Expand
Impact of Nausea and Vomiting on Quality of Life in Cancer Patients During Chemotherapy
TLDR
The evaluation of quality of life in randomized trials comparing different anti-emetic drugs for the prevention of chemotherapy-induced nausea and vomiting can add important information useful for the choice of the optimal antiemetic treatment. Expand
Quality of life consequences of chemotherapy-induced emesis
TLDR
The hypothesis that side-effects produced by chemotherapy and antiemetic therapy significantly contributed to changes in quality of life observed was supported. Expand
Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices.
TLDR
Although the introduction of 5-HT(3) receptor antagonist antiemetics has apparently led to a significant reduction in the frequency of post-treatment vomiting, there has been an accompanying increase in the duration of post -treatment nausea. Expand
A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study
TLDR
Olanzapine may be an effective agent for the prevention of chemotherapy-induced delayed emesis in cancer patients receiving their first cycle of chemotherapy consisting of cyclophosphamide, doxorubicin, platinum, and/or irinotecan. Expand
Improved control of emesis and quality of life with ondansetron in breast cancer.
TLDR
Ondansetron is an effective and well-toleratedAnti-emetic for patients receiving cyclophosphamide-based chemotherapy for the treatment of breast cancer and provides significant benefits for patients' quality of life compared with conventional anti-emetics. Expand
...
1
2
3
4
...